Adding to this, an inflamed tumor microenvironment created by high therapeutic doses of immune-perturbing antibody could also contribute to a further increased permeability and retention of 89Zr-DFO-CD8a in tumors 41,42. The gene discussed is CD8A; the disease is neoplasm.